

Connecting via Winsock to STN

7/8/02

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,  
STN AnaVist, now available  
NEWS 4 AUG 11 Derwent World Patents Index(R) web-based training during  
August  
NEWS 5 AUG 11 STN AnaVist workshops to be held in North America  
NEWS 6 AUG 30 CA/CAplus -Increased access to 19th century research documents  
NEWS 7 AUG 30 CASREACT - Enhanced with displayable reaction conditions  
NEWS 8 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* \* \* \* \* \* STN Columbus \* \* \* \* \* \* \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:15:36 ON 19 SEP 2005

=> fil reg			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
FULL ESTIMATED COST	ENTRY	SESSION	
	0.21	0.21	

FILE 'REGISTRY' ENTERED AT 18:15:41 ON 19 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2005 HIGHEST RN 863382-78-9  
DICTIONARY FILE UPDATES: 18 SEP 2005 HIGHEST RN 863382-78-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005


Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10615126.str



chain nodes :  
15 16 17 18 21  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13 14  
chain bonds :  
4-21 9-15 12-16 16-17 17-18  
ring bonds :  
1-2 1-6 2-3 2-11 3-4 3-14 4-5 4-7 5-6 5-10 7-8 8-9 9-10 11-12 12-13 13-14  
exact/norm bonds :  
9-15 12-16 16-17 17-18  
exact bonds :  
1-2 1-6 3-4 4-5 4-7 4-21 5-6 5-10 7-8 8-9 9-10  
normalized bonds :  
2-3 2-11 3-14 11-12 12-13 13-14  
isolated ring systems :

Ngrazier 10615126

containing 1 :

G1:Cy,Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:Atom 21:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Cy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 18:16:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 885 TO ITERATE

100.0% PROCESSED 885 ITERATIONS  
SEARCH TIME: 00.00.01

10 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 15916 TO 19484

PROJECTED ANSWERS: 11 TO 389

L2 10 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 18:16:23 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 18198 TO ITERATE

100.0% PROCESSED 18198 ITERATIONS  
SEARCH TIME: 00.00.01

277 ANSWERS

L3 277 SEA SSS FUL L1

=> fil caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'CAPLUS' ENTERED AT 18:16:29 ON 19 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.



FILE COVERS 1907 - 19 Sep 2005 VOL 143 ISS 13  
FILE LAST UPDATED: 18 Sep 2005 (20050918/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 13
L4      5 L3
=> d ed abs ibib hitstr 1-5
```

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 18 Jan 2004  
 GI



AB Title compds. I [wherein A = CR<sub>6</sub>R<sub>7</sub>R<sub>8</sub>R<sub>9</sub>, COCR<sub>10</sub>R<sub>11</sub>, or CR<sub>12</sub>=CR<sub>13</sub>; X and Y = independently H, F, Cl, Br, or alkyl; R<sub>1</sub> = alkyl, alkenyl, or (un)substituted benzyl; R<sub>2</sub> = (un)substituted (cyclo)alkyl(alkyl), alkenyl, alkynyl, (hetero)aryl(alkyl), or heterocyclyl(alkyl); R<sub>3</sub> = H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, heterocyclyl, or (hetero)aryl; R<sub>4</sub> = OH or NR<sub>14</sub>R<sub>15</sub>; R<sub>5</sub> = H, halo, OH, CN, or (un)substituted (cyclo)alkyl(oxy), alkenyl, alkynyl, (hetero)aryl(oxy), heterocyclyl(oxy), carbamoyl, sulfamoyl, acyl(oxy), etc.; R<sub>6</sub>-R<sub>9</sub> = independently H, alkyl, F, or OH; R<sub>10</sub> and R<sub>11</sub> = independently H or alkyl; R<sub>12</sub> and R<sub>13</sub> = independently H, F, or alkyl; R<sub>14</sub> and R<sub>15</sub> = independently H or alkyl; and pharmaceutically acceptable salts thereof] were prepared as glucocorticoid receptor agonists (no data). For example, (3S,4aR,10aR)-3-bromo-4a-ethyl-7-hydroxy-3,4,4a,9,10,10a-hexahydro-1H-phenanthren-2-one (multi-step preparation given) was treated with NaOH in DMF and H<sub>2</sub>O followed by 0.2M HCl to give a 2:1 mixture of the 2-keto-3-hydroxy and 2-hydroxy-3-keto derivs. The 2-keto enriched compound (9:1 ratio of 2-keto to 3-keto derivative) was alkylated with propyne in THF using BuLi in hexane to afford II (25%). Bioassays for glucocorticoid receptor modulation and antiinflammatory response are described, but no specific data are provided. Thus, I and their pharmaceutical compns., salts, and prodrugs are useful in the treatment of certain inflammatory disorders, endocrine disorders, collagen diseases, dermatol. diseases, allergic states, ophthalmic diseases, respiratory diseases, hematol. disorders, neoplastic diseases, edematous states, and gastrointestinal diseases (no data).

ACCESSION NUMBER: 2004:41424 CAPLUS  
 DOCUMENT NUMBER: 140:111136  
 TITLE: Preparation of octahydrophenanthrenols as glucocorticoid receptor modulators for treatment of inflammatory conditions  
 INVENTOR(S): Chantigny, Yves Andre; Kleinman, Edward Fox; Robinson, Ralph Pelton, Jr.  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: PCT Int. Appl., 143 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005229	A1	20040115	WO 2003-IB2941	20030625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491994	AA	20040115	CA 2003-2491994	20030625
EP 1521733	A1	20050413	EP 2003-740911	20030625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012575	A	20050503	BR 2003-12575	20030625
US 2004138262	A1	20040715	US 2003-615126	20030708
PRIORITY APPLN. INFO.:			US 2002-394425P	P 20020708
			WO 2003-IB2941	W 20030625

OTHER SOURCE(S) : MARPAT 140:111136

IT 645397-14-4P, (2R,3S,4AR,10aR)-4a-Ethyl-7-[(2-methylpyridin-3-yl)methyl]oxy]-2-(prop-1-ynyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-15-5P, (2R,3S,4AR,10aR)-4a-Ethyl-2-prop-1-ynyl-7-[(pyridin-2-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-16-6P, (2R,3S,4AR,10aR)-4a-Ethyl-2-prop-1-ynyl-7-[(pyridin-4-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-17-7P, (2R,3S,4AR,10aR)-7-[(2,4-Dimethylpyridin-3-yl)methyl]oxy]-4a-ethyl-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-18-8P, (2R,3S,4AR,10aR)-4a-Ethyl-2-prop-1-ynyl-7-[(pyridin-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-19-9P, (2R,3S,4AR,10aR)-4a-Ethyl-7-[[6-methylpyridin-3-yl)methyl]oxy]-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-20-2P, (2R,3S,4AR,10aR)-7-[[5-[(Diethylamino)methyl]-[1,2,4]oxadiazol-3-yl)methyl]oxy]-4a-ethyl-2-prop-1-ynyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645397-27-9P 645397-32-6P 645397-33-7P 645397-34-8P 645397-46-2P 645397-50-8P 645397-51-9P 645397-76-8P 645397-77-9P 645397-93-9P 645397-94-0P 645397-95-1P 645398-06-7P 645398-07-8P 645398-08-9P 645398-09-0P 645398-10-3P 645398-11-4P 645398-12-5P 645398-13-6P 645398-15-8P 645398-16-9P 645398-17-0P 645398-23-8P, (2R,3R,4AR,10aR)-4a-Ethyl-3-methyl-7-[(2-methylpyridin-3-yl)methyl]oxy]-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645398-26-1P, (2R,3R,4AR,10aR)-7-[[5-[2-(Azetidin-1-yl)ethyl]-[1,2,4]oxadiazol-3-yl)methyl]oxy]-4a-ethyl-3-methyl-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol 645398-27-2P 645398-28-3P, (2R,3R,4AR,10aR)-7-[[5-(2-Dimethylaminoethyl)-[1,2,4]oxadiazol-3-yl)methyl]oxy]-4a-ethyl-3-methyl-2-(pyridin-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,3-diol


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(glucocorticoid receptor modulator; preparation of octahydrophenanthrenols as glucocorticoid receptor modulators for treatment of inflammatory conditions)

RN 645397-14-4 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-2-(1-propynyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-15-5 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(2-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-16-6 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-17-7 CAPLUS

CN 2,3-Phenanthrenediol, 7-[(2,4-dimethyl-3-pyridinyl)methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-18-8 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(3-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-19-9 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-3-pyridinyl)methoxy]-2-(1-propynyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-20-2 CAPLUS

CN 2,3-Phenanthrenediol, 7-[[5-[(diethylamino)methyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-27-9 CAPLUS

CN 2,3-Phenanthrenediol, 2-(3-chloro-5-fluorophenyl)-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-32-6 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-7-(4-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-33-7 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-7-(3-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-34-8 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-2-phenyl-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-46-2 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-2-(4-fluorophenyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 645397-50-8 CAPLUS

CN 2,3-Phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-2-phenyl-4a-(phenylmethyl)-7-(4-pyridinylmethoxy)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-51-9 CAPLUS


CN 2,3-Phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-2-phenyl-4a-(phenylmethyl)-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-76-8 CAPLUS  
CN 2,3-Phenanthrenediol, 2-(2,6-difluorophenyl)-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-, (2R,3S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645397-77-9 CAPLUS  
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[(2-methyl-3-pyridinyl)methoxy]-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 645397-93-9 CAPLUS  
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-(1H-tetrazol-5-ylmethoxy)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-94-0 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-[3-(1H-tetrazol-5-yl)propoxy]-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645397-95-1 CAPLUS

CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-[4-(1H-tetrazol-5-yl)butoxy]-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 645398-06-7 CAPLUS

CN 2,3-Phenanthrenediol, 7-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-ylmethoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


## Absolute stereochemistry.



RN 645398-07-8 CAPLUS

2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[5-[(2-(4-morpholinyl)ethyl)-1,2,4-oxadiazol-3-yl]methoxy]-2-phenyl-,  
(2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)


## Absolute stereochemistry.



RN 645398-08-9 CAPLUS


CN 2,3-Phenanthrenediol, 7-[(5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl)methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 645398-09-0 CAPLUS  
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-[[5-[2-(1-piperidinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 645398-10-3 CAPLUS  
CN Acetamide, N-[3-[[[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy]methyl]-1,2,4-oxadiazol-5-yl]methyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-11-4 CAPLUS  
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[[5-[(1-methyl-1H-pyrrol-2-yl)methyl]-1,2,4-oxadiazol-3-yl]methoxy]-2-phenyl-, (2R,3R,4aR,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-12-5 CAPLUS  
CN Morpholine, 4-[[[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenyl-2-phenanthrenyl]oxy]acetyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-13-6 CAPLUS  
CN Piperazine, 1-[[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-phenanthrenyl]oxy]acetyl]-4-methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 645398-15-8 CAPLUS  
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[2-(4-morpholinyl)ethoxy]-2-phenyl-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-16-9 CAPLUS  
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-phenyl-7-[2-(1-piperidinyl)ethoxy]-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-17-0 CAPLUS  
CN 9(1H)-Phenanthrenone, 4a-ethyl-2,3,4,4a,10,10a-hexahydro-2,3-dihydroxy-3-methyl-7-[(2-methyl-3-pyridinyl)methoxy]-2-phenyl-, (2R,3R,4aR,10aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-23-8 CAPLUS  
CN 2,3-Phenanthrenediol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-7-[(2-methyl-3-pyridinyl)methoxy]-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-26-1 CAPLUS  
CN 2,3-Phenanthrenediol, 7-[[5-[2-(1-azetidinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-27-2 CAPLUS  
CN Acetamide, N-[3-[[[(4bR,6R,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-7-(2-pyridinyl)-2-phenanthrenyl]oxy]methyl]-1,2,4-oxadiazol-5-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 645398-28-3 CAPLUS  
CN 2,3-Phenanthrenediol, 7-[[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-3-methyl-2-(2-pyridinyl)-, (2R,3R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Ngrazier 10615126



AB Title compds. [I; R1 = alkyl, trifluoroalkyl, C.tplbond.CMe, C.tplbond.CCl, C.tplbond.CCF3, CF3, etc.; R2 = alkyl, alkenyl, (substituted) Ph; R3 = alkyl, amino, aminoalkyl, heterocycl, heterocyclalkyl; Q = (CH2)n; n= 1-3; with provisos], were prepared for treatment of obesity, diabetes, inflammation, anxiety, depression, and neurodegeneration (no data). Thus, ethanimidamide, N-hydroxy-2-[[4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl]oxy]- (preparation given) and NaH in THF were heated at 60° for 20 min. The solution was cooled to room temperature and ethyl-N,N-dimethylglycine was added. The resultant mixture was heated to reflux for 1 h to give 57% 2-phenanthrenol, 7-[[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, [2R-(2α,4aα,10aβ)].

ACCESSION NUMBER: 2002:330268 CAPLUS

DOCUMENT NUMBER: 136:340682

TITLE: Preparation of oxadiazolylalkoxyoctahydrophenanthrenes as glucocorticoid receptor modulators

INVENTOR(S): Liu, Kevin Kun-Chin; Morgan, Bradley P.; Robinson, Ralph Pelton

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 39 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1201660	A1	20020502	EP 2001-308789	20011016
EP 1201660	B1	20050831		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2360313	AA	20020430	CA 2001-2360313	20011026
US 2004014741	A1	20040122	US 2001-12274	20011026
US 6852719	B2	20050208		
JP 2002193955	A2	20020710	JP 2001-330283	20011029
BR 2001004834	A	20020820	BR 2001-4834	20011029
PRIORITY APPLN. INFO.:			US 2000-244302P	P 20001030
OTHER SOURCE(S):	MARPAT	136:340682		
IT 418771-78-5P	418771-80-9P	418771-83-2P		
418771-86-5P	418771-89-8P	418771-92-3P		

418771-94-5P 418771-97-8P 418772-00-6P  
418772-03-9P 418772-05-1P 418772-08-4P  
418772-10-8P 418772-12-0P 418772-13-1P  
418772-14-2P 418772-15-3P 418772-17-5P  
418772-18-6P 418772-19-7P 418772-20-0P  
418772-21-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxadiazolylalkoxyoctahydrophenanthrenes as glucocorticoid receptor modulators)

RN 418771-78-5 CAPLUS

CN 2-Phenanthrenol, 7-[[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 418771-80-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[5-[2-(4-morpholinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 418771-83-2 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[5-(1-piperidinylmethyl)-1,2,4-oxadiazol-3-yl]methoxy]-2-(trifluoromethyl)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418771-86-5 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[5-[2-(1-piperidinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418771-89-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[5-(1,2,5,6-tetrahydro-1-methyl-3-pyridinyl)-1,2,4-oxadiazol-3-yl]methoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418771-92-3 CAPLUS  
CN 2-Phenanthrenol, 7-[5-[2-(1-azetidinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418771-94-5 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[5-(1-methyl-3-piperidinyl)-1,2,4-oxadiazol-3-yl]methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418771-97-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[5-[2-(1-piperidinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 418772-00-6 CAPLUS  
CN 2-Phenanthrenol, 7-[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 418772-03-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[5-(1-piperidinylmethyl)-1,2,4-oxadiazol-3-yl]methoxy]-2-propyl-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 418772-05-1 CAPLUS

CN 2-Phenanthrenol, 7-[[5-[2-(1-azetidinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 418772-08-4 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[5-(1-methyl-3-piperidinyl)-1,2,4-oxadiazol-3-yl]methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418772-10-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[5-[2-(1-piperidinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-2-(trifluoromethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418772-12-0 CAPLUS  
CN 2-Phenanthrenol, 7-[[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418772-13-1 CAPLUS  
CN 2-Phenanthrenol, 7-[[5-[2-(1-azetidinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418772-14-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[5-(1-methyl-3-piperidinyl)-1,2,4-oxadiazol-3-yl]methoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 418772-15-3 CAPLUS  
CN 2-Phenanthrenol, 7-[5-[2-(diethylamino)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 418772-17-5 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 418772-18-6 CAPLUS

CN 2-Phenanthrenol, 7-[[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 418772-19-7 CAPLUS

CN 2-Phenanthrenol, 7-[[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 418772-20-0 CAPLUS

CN 2-Phenanthrenol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[[5-[2-(4-morpholinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-2-(1-propynyl)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 418772-21-1 CAPLUS

CN 2-Phenanthrenol, 4a-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-[ [5-(1-piperidinylmethyl)-1,2,4-oxadiazol-3-yl]methoxy]-2-(1-propynyl)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 03 May 2002  
 GI



AB Title compds. [I; R1 = (trifluoromethyl)alkyl, CF<sub>3</sub>, C.tplbond.CMe, C.tplbond.CCl, C.tplbond.CCF<sub>3</sub>, CH<sub>2</sub>O<sub>A</sub>; A = (trifluoromethyl)alkyl; R2 = alkyl, alkenyl, (substituted) Ph; R3 = H, alkyl, haloalkyl, alkenyl, alkynyl, haloalkynyl; R4 = H, alkylamino, alkylhet; R<sub>3</sub>R<sub>4</sub>N = het; het = (substituted) 5-7 membered (unsatd.) heterocyclic ring containing 1-3 of N, O, S; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic ring; and optionally substituted with 1-4 R<sub>7</sub>; R<sub>7</sub> = (substituted) alkyl; with provisos], were prepared for treatment of obesity, diabetes, depression, anxiety, neurodegeneration, and inflammatory disease (no data). A solution of 2,7-phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-ethyl-[2R-(2 $\alpha$ ,4 $\alpha$ ,10a $\beta$ )] (preparation given), COCl<sub>2</sub>, and Et<sub>3</sub>N in THF was stirred at room temperature for 3 h; 1-(2-aminoethyl)pyrrolidine was added followed by stirring overnight to give 41% carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-7-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester.

ACCESSION NUMBER: 2002:330263 CAPLUS  
 DOCUMENT NUMBER: 136:340495  
 TITLE: Preparation of octahydrophenanthrenyl carbamates as glucocorticoid receptor modulators  
 INVENTOR(S): Liu, Kevin Kun-Chin; Morgan, Bradley Paul; Robinson, Ralph Pelton, Jr.  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: Eur. Pat. Appl., 42 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1201649	A1	20020502	EP 2001-309064	20011025
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002193911	A2	20020710	JP 2001-328050	20011025
CA 2360308	AA	20020428	CA 2001-2360308	20011026
US 2002107235	A1	20020808	US 2001-6215	20011026
BR 2001004831	A	20020820	BR 2001-4831	20011026
PRIORITY APPLN. INFO.:			US 2000-243993P	P 20001028
OTHER SOURCE(S):	MARPAT	136:340495		
IT 419534-56-8P	419534-58-0P	419534-66-0P		
419534-68-2P	419534-70-6P	419534-72-8P		
419534-77-3P	419534-78-4P	419534-81-9P		

419534-82-0P 419534-84-2P 419534-94-4P  
419534-95-5P 419534-99-9P 419535-09-4P  
419535-10-7P 419535-12-9P 419535-13-0P  
419535-30-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of octahydrophenanthrenyl carbamates as glucocorticoid receptor modulators)

RN 419534-56-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-58-0 CAPLUS

CN 1-Piperazinecarboxylic acid, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-66-0 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419534-68-2 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-(2-hydroxyethyl)-, (4bS,7R,8aR)-  
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419534-70-6 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 2-(1-pyrrolidinylmethyl)-,  
(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 419534-72-8 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-(1-piperidinylmethyl)-,  
(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-77-3 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-methyl-,  
(4bS,7R,8aR)-4b,5,6,7,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-78-4 CAPLUS


CN 1-Azetidinecarboxylic acid, 3-(1-piperidinyl)-, (4bS,7R,8aR)-  
4b,5,6,7,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 419534-81-9 CAPLUS  
CN 1,4-Diazabicyclo[3.2.2]nonane-4-carboxylic acid, (4bS,7R,8aR)-  
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


## Absolute stereochemistry.



RN 419534-82-0 CAPLUS

CN 3,6-Diazabicyclo[3.2.2]nonane-3-carboxylic acid, 6-methyl-,  
(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


## Absolute stereochemistry.



RN 419534-84-2 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-2-carboxylic acid, octahydro-8-(hydroxymethyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester, (8R,9aS)- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 419534-94-4 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-(dimethylamino)-, (4bS,7R,8aR)-  
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419534-95-5 CAPLUS  
CN 1-Piperazinecarboxylic acid, 3,5-dimethyl-, (4bS,7R,8aR)-  
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 419534-99-9 CAPLUS  
CN 1H-1,4-Diazepine-1-carboxylic acid, hexahydro-4-methyl-,  
(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-09-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(dimethylamino)-2,2,6,6-tetramethyl-,  
(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-10-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[(dimethylamino)methyl]-,  
(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-12-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[(diethylamino)methyl]-,  
(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-  
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-13-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-30-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-(1-pyrrolidinylmethyl)-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


**Ngrazier 10615126**

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 11 May 2001  
 AB Compns. and methods are provided for achieving a therapeutic effect, including the treatment or prevention of syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a CRF antagonist alone or together with a glucocorticoid receptor antagonist.  
 ACCESSION NUMBER: 2001:338070 CAPLUS  
 DOCUMENT NUMBER: 134:336224  
 TITLE: Use of corticotropin releasing factor (CRF) antagonists for treating syndrome X  
 INVENTOR(S): Chen, Yuhpyng Liang; Hamanaka, Ernest Seiichi  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: Eur. Pat. Appl., 55 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1097709	A2	20010509	EP 2000-309441	20001026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 776724	B2	20040916	AU 2000-66695	20001024
ZA 2000006008	A	20020426	ZA 2000-6008	20001026
US 6589947	B1	20030708	US 2000-696822	20001026
CA 2325069	AA	20010429	CA 2000-2325069	20001027
NZ 507825	A	20041126	NZ 2000-507825	20001027
PRIORITY APPLN. INFO.:			US 1999-162340P	P 19991029


OTHER SOURCE(S): MARPAT 134:336224  
 IT 305822-13-3 305822-14-4 305822-22-4  
 305822-23-5 305822-25-7  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (CRF antagonist, alone or with glucocorticoid receptor antagonist, for treating syndrome X)  
 RN 305822-13-3 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305822-14-4 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-22-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-23-5 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-25-7 CAPLUS



CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 10 Nov 2000  
 GI



AB Title compds. [e.g., I; D = CR7, CR7R16, N, NR7, O' E = C, CR6, N; F = CR4, CR4R5, O; R = XR1; R1 = H, alkyl, acylalkyl, arylalkyl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = H, alkyl, arylalkyl, etc.; 1 of R2,R3 = null when adjacent dashed line = bond; R4,R5 = H, cyano, alkyl, alkoxy, etc.; R4R5 = O; R6 = H, cyano, alkyl, alkoxy, OH, etc.; R7,R16 = H, halo, cyano, alkyl, etc.; R7R16 = O; R8R9 = atoms to complete a substituted heteroarom. ring; R14,R15 = H, halo, alkyl, alkoxy, etc.; R14R15 = O when adjacent dashed lines = null; X = bond, CH2, CH(OH), CO; Z = (un)substituted CH2, -CH2CH2, -CH2CO, CO, etc.; dashed lines = optional bonds] were prepared as glucocorticoid receptor modulators (no data). E.g., 6-methoxy-2-tetralone was alkylated by formation of the pyrrolidine enamine and alkylation with benzyl bromide; the benzylated ketone then undergoes asym. Michael addition with Me vinyl ketone in the presence of (S)-(-)- $\alpha$ -methylbenzylamine followed by cyclocondensation with sodium methoxide to give a nonracemic methoxytetrahydrophenanthrenone derivative. E.g., demethylation of the methoxytetrahydrophenanthrenone with boron trichloride, reduction of the enone with lithium and ammonia, addition of 1-lithiopropyne to the ketone, formation of the aryl triflate with triflic anhydride and carbonylation with carbon monoxide in the presence in the presence of palladium acetate and bis(diphenylphosphino)propanol gives an hydroxyoctahydrophenanthrenecarboxylic acid derivative which is coupled with 4-(aminomethyl)pyridine in the presence of trimethylaluminum to give the octahydrophenanthrenecarboxamide II as one of the title compds.

ACCESSION NUMBER: 2000:790448 CAPLUS

DOCUMENT NUMBER: 133:350060

TITLE: Preparation of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors

INVENTOR(S): Dow, Robert Lee; Liu, Kevin Kun-Chin; Morgan, Bradley Paul; Swick, Andrew Gordon

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 279 pp.

CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066522	A1	20001109	WO 2000-IB366	20000327
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2372173	AA	20001109	CA 2000-2372173	20000327
BR 2000010138	A	20020122	BR 2000-10138	20000327
EP 1175383	A1	20020130	EP 2000-911172	20000327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103104	T2	20020521	TR 2001-200103104	20000327
JP 2002543169	T2	20021217	JP 2000-615356	20000327
EE 200100567	A	20030217	EE 2001-567	20000327
NZ 514465	A	20031128	NZ 2000-514465	20000327
AU 776608	B2	20040916	AU 2000-33165	20000327
US 6380223	B1	20020430	US 2000-559384	20000427
ZA 2001008846	A	20021028	ZA 2001-8846	20011026
NO 2001005272	A	20011228	NO 2001-5272	20011029
HR 2001000804	A1	20021231	HR 2001-804	20011030
BG 106142	A	20020531	BG 2001-106142	20011123
US 2002147336	A1	20021010	US 2002-80174	20020219
US 6699893	B2	20040302		
US 2003199527	A1	20031023	US 2003-413879	20030415
US 6777404	B2	20040817		
US 2004176595	A1	20040909	US 2003-721318	20031125
PRIORITY APPLN. INFO.:				
		US 1999-132130P	P	19990430
		US 1999-162340P	P	19991029
		WO 2000-IB366	W	20000327
		US 2000-559384	A3	20000427
		US 2000-696822	A3	20001026
		US 2002-80174	A1	20020219

OTHER SOURCE(S): MARPAT 133:350060


IT 305830-24-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of nonracemic octahydrophenanthrene and other tricyclic derivs.  
 as selective modulators of glucocorticoid receptors)

RN 305830-24-4 CAPLUS

CN 2-Phenanthrenol, 7-[(2-chloro-4-pyrimidinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT	305822-12-2P	305822-13-3P	305822-14-4P
	305822-15-5P	305822-16-6P	305822-17-7P
	305822-18-8P	305822-19-9P	305822-21-3P
	305822-22-4P	305822-23-5P	305822-24-6P
	305822-25-7P	305822-27-9P	305825-51-8P
	305825-55-2P	305825-60-9P	305825-61-0P
	305825-66-5P	305825-72-3P	305825-75-6P
	305825-76-7P	305826-00-0P	305826-06-6P
	305826-07-7P	305826-11-3P	305826-12-4P
	305826-18-0P	305826-20-4P	305826-21-5P
	305826-25-9P	305826-88-4P	305827-02-5P
	305827-09-2P	305827-10-5P	305827-46-7P
	305827-48-9P	305827-51-4P	305827-55-8P
	305827-70-7P	305827-72-9P	305827-82-1P
	305827-84-3P	305827-86-5P	305827-88-7P
	305827-90-1P	305828-01-7P	305828-05-1P
	305828-07-3P	305828-09-5P	305828-15-3P
	305828-17-5P	305828-23-3P	305828-25-5P
	305828-27-7P	305828-29-9P	305828-31-3P
	305828-32-4P	305828-39-1P	305828-40-4P
	305828-43-7P	305828-44-8P	305828-45-9P
	305828-46-0P	305828-47-1P	305828-48-2P
	305828-49-3P	305828-50-6P	305828-51-7P
	305828-52-8P	305828-53-9P	305828-54-0P
	305828-56-2P	305828-57-3P	305828-58-4P
	305828-59-5P	305828-60-8P	305828-62-0P
	305828-63-1P	305828-64-2P	305828-65-3P
	305828-66-4P	305828-67-5P	305828-69-7P
	305828-72-2P	305828-73-3P	305828-74-4P
	305828-75-5P	305828-76-6P	305828-77-7P
	305828-78-8P	305828-79-9P	305828-80-2P
	305828-81-3P	305828-82-4P	305828-83-5P
	305828-84-6P	305828-85-7P	305828-86-8P
	305828-87-9P	305828-88-0P	305828-89-1P
	305828-90-4P	305828-91-5P	305828-93-7P
	305828-94-8P	305828-95-9P	305828-96-0P
	305828-97-1P	305828-98-2P	305828-99-3P
	305829-00-9P	305829-01-0P	305829-02-1P
	305829-03-2P	305829-04-3P	305829-05-4P
	305829-06-5P	305829-07-6P	305829-08-7P
	305829-09-8P	305829-10-1P	305829-11-2P
	305829-13-4P	305829-14-5P	305829-15-6P
	305829-16-7P	305829-17-8P	305829-18-9P
	305829-23-6P	305829-24-7P	305829-25-8P
	305829-31-6P	305829-32-7P	305829-34-9P
	305829-35-0P	305829-36-1P	305829-37-2P
	305829-47-4P	305829-50-9P	305829-51-0P
	305829-52-1P	305829-53-2P	305829-54-3P
	305829-55-4P	305829-56-5P	305829-57-6P
	305829-58-7P	305829-59-8P	305829-60-1P


305829-65-6P 305829-66-7P 305829-67-8P  
 305829-68-9P 305829-69-0P 305829-70-3P  
 305829-71-4P 305829-72-5P 305829-73-6P  
 305829-74-7P 305829-75-8P 305829-76-9P  
 305829-77-0P 305829-78-1P 305829-79-2P  
 305829-81-6P 305829-82-7P 305829-83-8P  
 305829-84-9P 305829-85-0P 305829-86-1P  
 305829-88-3P 305829-89-4P 305829-90-7P  
 305829-91-8P 305829-92-9P 305829-94-1P  
 305829-97-4P 305830-00-6P 305830-01-7P  
 305830-02-8P 305830-03-9P 305830-04-0P  
 305830-05-1P 305830-21-1P 305830-22-2P  
 305830-37-9P 305830-47-1P 305830-54-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of nonracemic octahydrophenanthrene and other tricyclic derivs.  
 as selective modulators of glucocorticoid receptors)

RN 305822-12-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-13-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-14-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-15-5 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-16-6 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-17-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-18-8 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-19-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-4-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-21-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(pyrazinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-22-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-23-5 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-24-6 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 305822-25-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-27-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, (4bS,7R,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-51-8 CAPLUS

CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(pyrazinyloxy)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-55-2 CAPLUS

CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(2-pyrimidinylloxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-60-9 CAPLUS

CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(pyrazinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-61-0 CAPLUS

CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(pyrazinylmethoxy)-, monohydrochloride, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305825-66-5 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(4-pyridinylmethoxy)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-72-3 CAPLUS


CN 2-Phenanthrenol, 7-[[5-(2,6-dimethyl-4-morpholinyl)pentyl]oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305825-75-6 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[5-(1-piperidinyl)pentyl]oxy]-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305825-76-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-[[5-(1-pyrrolidinyl)pentyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305826-00-0 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methyl-1-butynyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305826-06-6 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(2-methylpropyl)-4a-

(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305826-07-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methylbutyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305826-11-3 CAPLUS


CN 2-Phenanthrenopropanol, 1,2,3,4,4a,9,10,10a-octahydro-2-hydroxy-alpha,alpha-dimethyl-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305826-12-4 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(4-methylpentyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305826-18-0 CAPLUS  
CN 2-Phenanthrenol, 2-(cyclopropylethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305826-20-4 CAPLUS  
CN 2-Phenanthrenol, 2-(3,3-dimethyl-1-butynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305826-21-5 CAPLUS

CN 2-Phenanthrenepropanol, 1,2,3,4,4a,9,10,10a-octahydro-2-hydroxy-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305826-25-9 CAPLUS

CN 2-Phenanthrenol, 2-(2-cyclopropylethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305826-88-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, (4bS,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-02-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-methyl-, (4bS,8aR)-4b-[ [3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-09-2 CAPLUS

CN 1-Piperidinocarboxylic acid, 4-(dimethylamino)-, (4bS,7R,8aR)-4b-[ [3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-10-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-acetyl-, (4bS,7R,8aR)-4b-[ [3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-46-7 CAPLUS

CN Piperazine, 1-methyl-4-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-48-9 CAPLUS

CN Piperidine, 1-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]acetyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-51-4 CAPLUS


CN 2-Phenanthrenol, 7-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305827-55-8 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 305827-70-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-pyrimidinyloxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-72-9 CAPLUS

CN 2-Phenanthrenol, 7-[(2-amino-6-methyl-4-pyrimidinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-82-1 CAPLUS

CN 2-Phenanthrenol, 7-[[5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-84-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[5-(1-piperidinylmethyl)-1,2,4-oxadiazol-3-yl]methoxy]-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-86-5 CAPLUS

CN 2-Phenanthrenol, 7-[(4,6-dimethoxy-1,3,5-triazin-2-yl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-88-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[[3-(1-piperidinylmethyl)-1,2,4-oxadiazol-5-yl]methoxy]-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-90-1 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]methoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-01-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-7-(pyrazinylloxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-05-1 CAPLUS

CN 2-Phenanthrenol, 7-[(4-chloro-2-pyrimidinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-07-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[3-(1-piperidinylmethyl)-1,2,4-oxadiazol-5-yl]methoxy]-4a-propyl-2-(1-propynyl)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-09-5 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-7-[[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]methoxy]-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-15-3 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methoxy-2-pyrimidinyl)oxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 305828-17-5 CAPLUS  
CN Morpholine, 4-[[6-[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-23-3 CAPLUS  
CN 2-Phenanthrenol, 7-[(5-amino-1H-1,2,4-triazol-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-25-5 CAPLUS

CN Pyridine, 3,3'-[[(2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-2,7-phenanthrediyil]bis(oxymethylene)]bis-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-27-7 CAPLUS

CN Pyridine, 4,4'-[[(2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-2,7-phenanthrediyil]bis(oxymethylene)]bis-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-29-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(pyrazinyloxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-31-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-32-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(2-pyridinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-39-1 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-40-4 CAPLUS

CN 2-Phenanthrenol, 7-[(2,6-dimethoxy-4-pyrimidinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-43-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[3-(1-pyrrolidinyl)pyrazinyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-44-8 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[6-(1-pyrrolidinyl)-4-pyrimidinyl]oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-45-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[(6-(1-pyrrolidinyl)-2-pyridinyl)oxy]-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305828-46-0 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[(6-(1-pyrrolidinyl)pyrazinyl)oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-47-1 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(pyrazinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-48-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[2-(1-piperazinyl)ethoxy]-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-49-3 CAPLUS  
CN Piperazine, 1-acetyl-4-[2-[[4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-50-6 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(2-pyrimidinyloxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-51-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(pyrazinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-52-8 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(3-pyridinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


✓



RN 305828-53-9 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-54-0 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethoxy]-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-56-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-4a-pentyl-2-(1-propynyl)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-57-3 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(5-pyrimidinylmethoxy)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-58-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(4-pyrimidinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-59-5 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[(2-(1-pyrrolidinyl)-4-pyridinyl)methoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-60-8 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-  
[[6-(1-pyrrolidinyl)-3-pyridinyl]methoxy]-, (2R,4aR,10aR)- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 305828-62-0 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-  
4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-63-1 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-  
4a-(phenylmethyl)-2-propyl-, hydrochloride, (2R,4aS,10aR)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305828-64-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-  
2,4a-dipropyl-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-65-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-7-(2-piperidinylmethoxy)-2-propyl-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-66-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-[1-(4-pyridinyl)ethoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


✓



RN 305828-67-5 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-4a-pentyl-2-propyl-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-69-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-propyl-7-(4-pyridinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-72-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(pyrazinylloxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-73-3 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(2-pyrimidinylloxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-74-4 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(3-methylpyrazinyl)oxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-75-5 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(3-methyl-2-quinoxalinyl)oxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-76-6 CAPLUS  
CN 2-Phenanthrenol, 7-[(3,6-dimethylpyrazinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-77-7 CAPLUS  
CN 2-Phenanthrenol, 7-[2-amino-6-methyl-4-pyrimidinyl]oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-78-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-2-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



✓

RN 305828-79-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-2-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-80-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-[[4-(trifluoromethyl)-2-pyrimidinyl]oxy]-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-81-3 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[(4-(trifluoromethyl)-2-pyrimidinyl)oxy]-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-82-4 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-83-5 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 305828-84-6 CAPLUS  
CN Pyridine, 3,3'-[[(2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-2,7-phenanthrenediyl]bis(oxymethylene)]bis[6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-85-7 CAPLUS  
CN 2-Pyridinecarbonitrile, 6-[[[[4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 305828-86-8 CAPLUS

CN 2-Pyridinecarbonitrile, 6-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]methyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-87-9 CAPLUS

CN 2-Phenanthrenol, 7-[(3-amino-4-methyl-2-pyridinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-88-0 CAPLUS

CN 2-Phenanthrenol, 7-[(3-amino-2-pyridinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-89-1 CAPLUS

CN 3-Pyridinecarbonitrile, 6-methyl-2-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-90-4 CAPLUS

CN 3-Pyridinecarbonitrile, 6-methyl-2-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-91-5 CAPLUS


CN 3-Pyridinecarbonitrile, 2-[[<sup>4bS,7R,8aR</sup>-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-93-7 CAPLUS

CN 2-Pyridinecarbonitrile, 6-[[4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)



RN 305828-94-8 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[[6-(trifluoromethyl)-2-pyridinyl]oxy]- (9CI) (CA INDEX NAME)



RN 305828-95-9 CAPLUS


CN 2-Pyridinecarbonitrile, 6-[[<sup>4bS,7R,8aR</sup>-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-96-0 CAPLUS  
CN 3-Pyridinecarbonitrile, 4,6-dimethyl-2-[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-97-1 CAPLUS  
CN 3-Pyridinecarbonitrile, 6-[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-98-2 CAPLUS  
CN 3-Pyridinecarbonitrile, 6-[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-99-3 CAPLUS

CN 3-Pyridinecarbonitrile, 4,6-dimethyl-2-[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy] - (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305829-00-9 CAPLUS

CN 2-Phenanthrenol, 7-[(2,6-dichloro-4-pyrimidinyl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-01-0 CAPLUS


CN 2-Phenanthrenol, 7-[(2,6-dimethoxy-4-pyrimidinyl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-02-1 CAPLUS  
CN 2-Phenanthrenol, 7-[{(2-chloro-6-methyl-4-pyridinyl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-03-2 CAPLUS  
CN 2-Phenanthrenol, 7-[(6-chloro-2-pyridinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-04-3 CAPLUS  
CN 2-Pyridinecarbonitrile, 3-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-05-4 CAPLUS

CN 2-Pyridinecarbonitrile, 3-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-06-5 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methoxy-6-methyl-4-pyridyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-07-6 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2- (1-

propynyl)-7-(2-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-08-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(2-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-09-8 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[ (2-methoxy-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-10-1 CAPLUS

CN 2(1H)-Pyridinone, 3-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX

NAME)


Absolute stereochemistry.



RN 305829-11-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(4-pyrimidinylmethoxy)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-13-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-methyl-2-[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-14-5 CAPLUS

CN 2-Phenanthrenol, 7-[(4,6-dimethyl-2-pyrimidinyl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR) -

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-15-6 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(3-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-16-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(4-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-17-8 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[3-methyl-2-quinoxalinyl]methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-18-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methyl-3-isoxazolyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-23-6 CAPLUS  
CN 3-Pyridinecarbonitrile, 6-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-24-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methoxypropyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX)

NAME)


Absolute stereochemistry.



RN 305829-25-8 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methoxy-2-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-31-6 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(methoxymethyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-32-7 CAPLUS  
CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-34-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-5-thiazolyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-35-0 CAPLUS  
CN 2-Phenanthrenol, 7-[[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-36-1 CAPLUS

CN 2-Phenanthrenol, 7-[5-[(3,5-dimethyl-4-isoxazolyl)-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-37-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methoxy-1-propynyl)-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-47-4 CAPLUS


CN 2-Phenanthrenol, 2-(3,3-dimethylbutyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-50-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(2-phenylethyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-51-0 CAPLUS  
CN 2-Phenanthrenol, 2-[cyclopropylmethoxy]methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-52-1 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-[(2,2,2-trifluoroethoxy)methyl]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-53-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(1-methylethoxy)methyl]-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-54-3 CAPLUS

CN 2-Phenanthrenol, 2-(azidomethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-55-4 CAPLUS


CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-[(2-pyridinylmethoxy)methyl]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-56-5 CAPLUS  
CN Propanenitrile, 3-[(2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-2-hydroxy-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-phenanthrenyl]methoxy] - (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 305829-57-6 CAPLUS  
CN 2-Phenanthrenol, 2-[(cyclopentyloxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-58-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(3-methyl-3-oxetanyl)methoxymethyl]-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-59-8 CAPLUS

CN 2-Phenanthrenol, 2-[(1,1-dimethylethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR) - (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305829-60-1 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(phenoxyethyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR) - (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305829-65-6 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-[2-(2-pyridinyl)ethyl]-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR) - (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305829-66-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(methylthio)methyl]-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-67-8 CAPLUS

CN 2-Phenanthrenol, 2-[(cyclobutyloxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-68-9 CAPLUS

CN 2-Phenanthrenol, 2-[(2-fluoroethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-

4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-69-0 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(2-methylthio)ethoxy]methyl]-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-70-3 CAPLUS

CN 2-Phenanthrenol, 2-[(2,2-dimethylpropoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-71-4 CAPLUS

CN 2-Phenanthrenol, 2-[(2-ethylbutoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-72-5 CAPLUS

CN 2-Phenanthrenol, 2-[(2-butynyloxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-73-6 CAPLUS


CN 2-Phenanthrenol, 2-[(cyclohexylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-74-7 CAPLUS  
CN 2-Phenanthrenol, 2-[(cyclopentylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)

## Absolute stereochemistry.




RN 305829-75-8 CAPLUS  
CN 2-Phenanthrenol, 2-[(cyclobutylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI)  
(CA INDEX NAME)

## Absolute stereochemistry.



RN 305829-76-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-[(3-phenyl-1-propynyl)oxy]methyl]-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


## Absolute stereochemistry.



RN 305829-77-0 CAPLUS

CN 2-Phenanthrenol, 2-[(3-fluoro-3-methyl-1-butynyl)oxy]methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-78-1 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(1H-imidazol-1-ylmethyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-79-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-(1H-1,2,4-triazol-1-ylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-81-6 CAPLUS

CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-82-7 CAPLUS

CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methyl-3-isoxazolyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-83-8 CAPLUS

CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-84-9 CAPLUS

CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(pyrazinyloxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-85-0 CAPLUS

CN 2-Phenanthrenol, 7-[(2-amino-6-methyl-4-pyrimidinyl)oxy]-2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-86-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-[[4bS,7R,8aR]-7-(ethoxymethyl)-4b,5,6,7,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-88-3 CAPLUS

CN 2-Phenanthrenol, 2-(cyclopropylethynyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305829-89-4 CAPLUS

CN 2-Phenanthrenol, 2-(cyclopropylethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-90-7 CAPLUS

CN 2-Phenanthrenol, 2-(2-cyclopropylethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-91-8 CAPLUS

CN 2-Phenanthrenol, 2-(2-cyclopropylethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305829-92-9 CAPLUS

CN 2-Pyridinecarbonitrile, 3-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-94-1 CAPLUS

CN 2-Phenanthrenol, 2-[(cyclobutyloxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(1-oxido-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305829-97-4 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-[2-(1H-pyrazol-1-yl)ethoxy]methyl]-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305830-00-6 CAPLUS

CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-4-thiazolyl)methoxy]-4a-(phenylmethyl)-,  
(2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305830-01-7 CAPLUS

CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methyl-3-isoxazolyl)methoxy]-4a-(phenylmethyl)-,  
(2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305830-02-8 CAPLUS

CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-4-thiazolyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305830-03-9 CAPLUS

CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305830-04-0 CAPLUS


CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 305830-05-1 CAPLUS  
CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.



RN 305830-21-1 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(1-methylethoxy)methyl]-  
7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)


## Absolute stereochemistry.



RN 305830-22-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-[(2,2,2-trifluoroethoxy)methyl]-,

(2R,4aS,10aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305830-37-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-2-(1-pentynyl)-4a-(phenylmethyl)-, (2R,4aS,10aR) - (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




✓

RN 305830-47-1 CAPLUS

CN 2-Phenanthrenol, 2-(1-butynyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

✓




RN 305830-54-0 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-methyl-7-[(2-methyl-3-

pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 305822-69-9P 305823-16-9P 305823-19-2P  
305823-20-5P 305823-24-9P 305823-25-0P  
305823-27-2P 305823-28-3P 305823-29-4P  
305823-30-7P 305823-32-9P 305823-33-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of nonracemic octahydrophenanthrene and other tricyclic derivs.  
as selective modulators of glucocorticoid receptors)

RN 305822-69-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[5-(4-morpholinyl)pentyl]oxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 305823-16-9 CAPLUS

CN 4-Morpholinecarboxylic acid, (4bS,7R,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-19-2 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[(3-pyrazinyl-1,2,4-oxadiazol-5-yl)methoxy]-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-20-5 CAPLUS

CN 2-Phenanthrenol, 7-[(5-amino-1H-1,2,4-triazol-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-24-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(1H-tetrazol-5-ylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-25-0 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-methyl-1-piperazinyl)ethoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-27-2 CAPLUS

CN 2-Phenanthrenol, 7-[[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-28-3 CAPLUS

CN 1,2,4-Oxadiazol-5(2H)-one, 3-[[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-29-4 CAPLUS

CN 1,2,4-Oxadiazole-5(2H)-thione, 3-[[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-30-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[[5-[2-(4-morpholinyl)ethyl]-1,2,4-oxadiazol-3-yl]methoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-32-9 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(pyrazinyloxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-33-0 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-(4-morpholinyl)-4-pyrimidinyl)oxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Ngrazier 10615126


=> log y		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	25.15	186.69
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.65	-3.65

STN INTERNATIONAL LOGOFF AT 18:17:07 ON 19 SEP 2005

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 11 May 2001  
 AB Compns. and methods are provided for achieving a therapeutic effect, including the treatment or prevention of syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a CRF antagonist alone or together with a glucocorticoid receptor antagonist.  
 ACCESSION NUMBER: 2001:338070 CAPLUS  
 DOCUMENT NUMBER: 134:336224  
 TITLE: Use of corticotropin releasing factor (CRF) antagonists for treating syndrome X  
 INVENTOR(S): Chen, Yuhpyng Liang; Hamanaka, Ernest Seiichi  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: Eur. Pat. Appl., 55 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1097709	A2	20010509	EP 2000-309441	20001026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 776724	B2	20040916	AU 2000-66695	20001024
ZA 2000006008	A	20020426	ZA 2000-6008	20001026
US 6589947	B1	20030708	US 2000-696822	20001026
CA 2325069	AA	20010429	CA 2000-2325069	20001027
NZ 507825	A	20041126	NZ 2000-507825	20001027
PRIORITY APPLN. INFO.:			US 1999-162340P	P 19991029
OTHER SOURCE(S): MARPAT 134:336224				
IT 305822-13-3 305822-14-4 305822-22-4 305822-23-5 305822-25-7				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (CRF antagonist, alone or with glucocorticoid receptor antagonist, for treating syndrome X)				
RN 305822-13-3 CAPLUS				
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 305822-14-4 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-22-4 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305822-23-5 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 305822-25-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
 ED Entered STN: 10 Nov 2000  
 GI



**AB** Title compds. (e.g., I; D = CR7, CR7R16, N, NR7, O' E = C, CR6, N; F = CR4, CR4R5, O; R = XRI; R1 = H, alkyl, acylalkyl, arylalkyl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = H, alkyl, arylalkyl, etc.; 1 of R2,R3 = null when adjacent dashed line = bond; R4,R5 = H, cyano, alkyl, alkoxy, etc.; R4R5 = O; R6 = H, cyano, alkyl, alkoxy, OH, etc.; R7,R16 = H, halo, cyano, alkyl, etc.; R7R16 = O; R8R9 = atoms to complete a substituted heteroarom. ring; R14,R15 = H, halo, alkyl, alkoxy, etc.; R14R15 = O when adjacent dashed lines = null; X = bond, CH2, CH(OH), CO, Z = (un)substituted CH2, -CH2CH2, -CH2CO, CO, etc.; dashed lines = optional bonds) were prepared as glucocorticoid receptor modulators (no data). E.g., 6-methoxy-2-tetralone was alkylated by formation of the pyrrolidine enamine and alkylation with benzyl bromide; the benzylated ketone then undergoes asym. Michael addition with Me vinyl ketone in the presence of (S)-(-)- $\alpha$ -methylbenzylamine followed by cyclocondensation with sodium methoxide to give a nonracemic methoxytetralinophenanthrene derivative. E.g., demethylation of the methoxytetralinophenanthrene with boron trichloride, reduction of the enone with lithium and ammonia, addition of 1-lithiopropyne to the ketone, formation of the aryl triflate with triflic anhydride and carbonylation with carbon monoxide in the presence in the presence of palladium acetate and bis(diphenylphosphino)propanol gives an hydroxyoctahydrophenanthrenecarboxylic acid derivative which is coupled with 4-(aminomethyl)pyridine in the presence of trimethylaluminum to give the octahydrophenanthrenecarboxamide II as one of the title compds.

ACCESSION NUMBER: 2000:190448 CAPLUS

DOCUMENT NUMBER: 133:350060

TITLE: Preparation of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors

INVENTOR(S): Dow, Robert Lee; Liu, Kevin Kun-Chin; Morgan, Bradley

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: PCT Int. Appl., 279 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000065522	A1	20001109	WO 2000-IB366	20000327
W: AZ, AL, AM, AT, AU, BE, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HA, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MM, SD, SL, SZ, TZ, UG, ZN, AT, BE, CH, CY, DE, DK, ES, FI, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2372173	AA	20001109	CA 2000-2372173	20000327
BR 2000010138	A	20020122	BR 2000-101138	20000327
EP 1175383	A1	20020130	EP 2000-911172	20000327
R: AT, BE, CH, DE, DK, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103104	T2	20020521	TR 2001-200103104	20000327
JP 2002543169	T2	20021217	JP 2000-615356	20000327
SE 200100567	A	20030217	SE 2001-567	20000327
N 514462	A	20031128	NZ 2000-514465	20000327
AU 776608	B2	20040916	AU 2000-33165	20000327
US 6380223	B1	20042040	US 2000-559384	20000427
ZA 2001008846	A	20021208	ZA 2001-8846	20011026
NO 200105272	A	20011228	NO 2001-5272	20011029
HR 200100804	A1	20021231	HR 2001-804	20011030
BG 106142	A	20020531	BG 2001-106142	20011123
US 2002147336	A1	20021010	US 2002-80174	20020219
US 6699893	B2	20040302		
US 200319527	A1	20031023	US 2003-413879	20030415
US 6777404	B2	20040817		
US 2004176595	A1	20040309		


PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 133:350060  
 IT 305830-24-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or agent); USES (Uses)  
 (prep. of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors)  
 RN 305830-24-4 CAPLUS  
 CN 2-Phenanthrenol, 7-((2-chloro-4-pyrimidinyl)oxy)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

INDEX NAME)

Absolute stereochemistry.




IT 305822-12-2P 305822-13-3P 305822-14-4P  
 305822-15-5P 305822-16-6P 305822-17-7P  
 305822-18-8P 305822-19-9P 305822-21-3P  
 305822-22-4P 305822-23-5P 305822-24-6P  
 305822-25-7P 305822-27-PP 305825-51-8P  
 305825-55-2P 305825-60-9P 305825-61-0P  
 305825-66-5P 305825-72-3P 305825-75-6P  
 305825-76-7P 305826-00-0P 305826-06-6P  
 305826-07-7P 305826-11-3P 305826-12-4P  
 305826-18-0P 305826-20-4P 305826-21-5P  
 305826-25-9P 305826-88-4P 305827-02-5P  
 305827-09-2P 305827-10-5P 305827-46-7P  
 305827-48-9P 305827-51-4P 305827-55-8P  
 305827-70-7P 305827-72-9P 305827-82-1P  
 305827-84-3P 305827-86-5P 305827-88-7P  
 305827-90-1P 305828-01-7P 305828-05-1P  
 305828-07-3P 305828-09-5P 305828-15-3P  
 305828-17-5P 305828-23-3P 305828-25-5P  
 305828-27-7P 305828-29-9P 305828-31-3P  
 305828-32-4P 305828-39-1P 305828-40-4P  
 305828-43-7P 305828-44-8P 305828-45-9P  
 305828-46-0P 305828-47-1P 305828-48-2P  
 305828-49-3P 305828-50-6P 305828-51-7P  
 305828-52-8P 305828-53-9P 305828-54-0P  
 305828-56-2P 305828-57-3P 305828-58-4P  
 305828-59-5P 305828-60-8P 305828-62-0P  
 305828-63-1P 305828-64-2P 305828-65-3P  
 305828-66-4P 305828-67-5P 305828-69-7P  
 305828-72-2P 305828-73-3P 305828-74-4P  
 305828-75-5P 305828-76-6P 305828-77-7P  
 305828-78-8P 305828-79-9P 305828-80-2P  
 305828-81-3P 305828-82-4P 305828-83-5P  
 305828-84-6P 305828-85-7P 305828-86-8P  
 305828-87-9P 305828-88-0P 305828-89-1P  
 305828-90-4P 305828-91-5P 305828-93-7P  
 305828-94-8P 305828-95-9P 305828-96-0P  
 305828-97-1P 305828-98-2P 305828-99-3P  
 305829-00-9P 305829-01-0P 305829-02-1P  
 305829-03-2P 305829-04-3P 305829-05-4P  
 305829-06-5P 305829-07-6P 305829-08-7P  
 305829-09-8P 305829-10-1P 305829-11-2P  
 305829-13-4P 305829-14-5P 305829-15-6P  
 305829-16-7P 305829-17-8P 305829-18-9P  
 305829-23-6P 305829-24-7P 305829-25-8P  
 305829-31-6P 305829-32-7P 305829-34-9P  
 305829-35-0P 305829-36-1P 305829-37-2P  
 305829-47-4P 305829-50-9P 305829-51-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prep. of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors)


RN 305822-12-2 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305822-13-3 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-14-4 CAPLUS


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305822-15-5 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-16-6 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 INDEX NAME)

Absolute stereochemistry.




RN 305822-21-3 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-(pyrazinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-22-4 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-23-5 CAPLUS

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305822-17-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305822-18-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-19-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-4-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-24-6 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-2-(3,3,3-trifluoropropyl)-, (2S,4aS,10aR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 305822-25-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 305822-27-9 CAPLUS  
 CN 1-Pyrazolidinecarboxylic acid, (4bS,7R,8aR)-7-(chloroethyl)-4b,5,6,7,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305825-51-8 CAPLUS  
 CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(pyrazinylxylo)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305825-55-2 CAPLUS  
 CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(2-pyrimidinylxylo)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305825-60-9 CAPLUS  
 CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(pyrazinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305825-72-3 CAPLUS  
 CN 2-Phenanthrenol, 7-[(5-(2,6-dimethyl-4-morpholinyl)pentyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305825-75-6 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[(5-(1-piperidinyl)pentyl)oxy]-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305825-76-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-[(5-(1-pyrazolidinyl)pentyl)oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 Absolute stereochemistry.



RN 305825-61-0 CAPLUS  
 CN 2-Phenanthrenol, 4a-butyl-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-7-(pyridinylmethoxy)-, monohydrochloride, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• HCl

RN 305825-66-5 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(4-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 Absolute stereochemistry.




RN 305826-00-0 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methyl-1-butynyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305826-06-6 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(2-methylpropyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305826-07-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methylbutyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Absolute stereochemistry.




RN 305826-11-3 CAPLUS  
CN 2-Phenanthrenepropanol, 1,2,3,4,4a,9,10,10a-octahydro-2-hydroxy-alpha,alpha-dimethyl-4-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305826-12-4 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(4-methylpentyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305826-25-9 CAPLUS  
CN 2-Phenanthrenol, 2-(2-cyclopropylethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305826-88-4 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, (4bS,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-02-5 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-methyl-, (4bS,8aR)-4b-[{3-(dimethylamino)phenyl}methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305826-18-0 CAPLUS  
CN 2-Phenanthrenol, 2-(cyclopropylethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305826-20-4 CAPLUS  
CN 2-Phenanthrenol, 2-(3,3-dimethyl-1-butynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305826-21-5 CAPLUS  
CN 2-Phenanthrenepropanol, 1,2,3,4,4a,9,10,10a-octahydro-2-hydroxy-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305827-09-2 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-(dimethylamino)-, (4bS,7R,8aR)-4b-[{3-(dimethylamino)phenyl}methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-10-5 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-acetyl-, (4bS,7R,8aR)-4b-[{3-(dimethylamino)phenyl}methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-46-7 CAPLUS  
CN Piperazine, 1-methyl-4-[[{4bS,7R,8aR}-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]acetyl- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Absolute stereochemistry.




RN 305827-48-9 CAPLUS  
CN Piperidine, 1-[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]acetyl]-4-(1-pyrrolidinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-51-4 CAPLUS  
CN 2-Phenanthrenol, 7-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-(2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-55-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-(1-pyrrolidinyl)ethoxy)-(9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305827-84-3 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[(5-(1-piperidinylmethyl)-1,2,4-oxadiazol-3-yl)methoxy]-2-(1-propynyl)-(2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305827-86-5 CAPLUS  
CN 2-Phenanthrenol, 7-[(4,6-dimethoxy-1,3,5-triazin-2-yl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-(2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-88-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-[(3-(1-piperidinylmethyl)-1,2,4-oxadiazol-5-yl)methoxy]-2-(1-propynyl)-(2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305827-70-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-pyrimidinyl)oxy)-(2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305827-72-9 CAPLUS  
CN 2-Phenanthrenol, 7-[(2-amino-6-methyl-4-pyrimidinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-(2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-82-1 CAPLUS  
CN 2-Phenanthrenol, 7-[(5-[2-(dimethylamino)ethyl]-1,2,4-oxadiazol-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-(2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305827-90-1 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[(3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl)methoxy)-(2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-01-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-7-(pyrazinyl)oxy)-(2R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-05-1 CAPLUS  
CN 2-Phenanthrenol, 7-[(4-chloro-2-pyrimidinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-(2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-07-3 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(3-(1-piperidinylmethyl)-1,2,4-oxadiazol-5-yl)methoxy]-4a-propyl-2-(1-propynyl)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-09-5 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-7-[(3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl)methoxy]-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-15-3 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methoxy-2-pyrimidinyl)oxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)




RN 305828-27-7 CAPLUS  
CN Pyridine, 4,4'-[{(2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-2,7-phenanthrediyil]bis(oxymethylene)]bis-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-29-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(pyrazinylxylo)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-31-3 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-17-5 CAPLUS  
CN Morpholine, 4-[(6-[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy)-3-pyridinyl]carbonyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-23-3 CAPLUS  
CN 2-Phenanthrenol, 7-[(5-amino-1H-1,2,4-triazol-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-propyl-2-(1-propynyl)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-25-5 CAPLUS  
CN Pyridine, 3,3'-[{(2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-2,7-phenanthrediyil]bis(oxymethylene)}bis-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-32-4 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(2-pyridinylmethyl)-, (2R,4aR,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-39-1 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-40-4 CAPLUS  
CN 2-Phenanthrenol, 7-[(2,6-dimethoxy-4-pyrimidinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-43-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[3-(1-pyrrolidinyl)pyrazinyl]oxy-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-44-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[6-(1-pyrrolidinyl)-4-pyrimidinyl]oxy-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-45-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[6-(1-pyrrolidinyl)-2-pyridinyl]oxy-, (2R,4aS,10aR)- (9CI)

Absolute stereochemistry.




RN 305828-49-3 CAPLUS  
CN Piperazine, 1-acetyl-4-[2-[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-50-6 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(2-pyrimidinyl)oxy-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305828-51-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(pyrazinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 305828-46-0 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[6-(1-pyrrolidinyl)pyrazinyl]oxy-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-47-1 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(pyrazinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-48-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-(1-piperazinyl)ethoxy)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-52-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(3-pyridinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-53-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(4-pyridinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-54-0 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[2-(4-(2-pyridinyl)-1-piperazinyl)ethoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-56-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-(2-(4-morpholinyl)ethoxy)-4a-pentyl-2-(1-pyrrolidinyl)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-57-3 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-(5-pyrimidinylmethoxy)-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-58-4 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(4-pyrimidinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-62-0 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-63-1 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-(2-(4-morpholinyl)ethoxy)-4a-(phenylmethyl)-2-propyl-, hydrochloride, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• HCl


RN 305828-64-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-(2-(4-morpholinyl)ethoxy)-2,4a-dipropyl-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-59-5 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-((2-(1-pyrrolidinyl)-4-pyridinyl)methoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-60-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-(1-propynyl)-7-([(6-(1-pyrrolidinyl)-3-pyridinyl)methoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-65-3 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-7-(2-piperidinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-66-4 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-[(4-pyridinyl)ethoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-67-5 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-(2-(4-morpholinyl)ethoxy)-4a-pentyl-2-propyl-, (2R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-69-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-pentyl-2-propyl-7-(4-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-72-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(pyrazinyl oxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-73-3 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(2-pyrimidinyl oxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-77-7 CAPLUS  
CN 2-Phenanthrenol, 7-[(2-amino-6-methyl-4-pyrimidinyl) oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-78-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-2-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-79-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-2-pyridinyl)methoxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-74-4 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(3-methylpyrazinyl) oxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-75-5 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(3-methyl-2-quinoxalinyl) oxy]-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-76-6 CAPLUS  
CN 2-Phenanthrenol, 7-[(3,6-dimethylpyrazinyl) oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-80-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-[(4-(trifluoromethyl)-2-pyrimidinyl) oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-81-3 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[(4-(trifluoromethyl)-2-pyrimidinyl) oxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-82-4 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methyl-3-pyridinyl) methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-83-5 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-((6-methyl-3-pyridinyl)methoxy)-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-84-6 CAPLUS  
CN Pyridine, 3,3'-[[(2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-2,7-phenanthrenediyl]bis(oxymethylene)]bis(6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305828-88-0 CAPLUS  
CN 2-Phenanthrenol, 7-((3-amino-2-pyridinyl)oxy)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-89-1 CAPLUS  
CN 3-Pyridinecarbonitrile, 6-methyl-2-((4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl)oxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-90-4 CAPLUS  
CN 3-Pyridinecarbonitrile, 6-methyl-2-((4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl)oxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 305828-85-7 CAPLUS  
CN 2-Pyridinecarbonitrile, 6-[[((4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl)oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-86-8 CAPLUS  
CN 2-Pyridinecarbonitrile, 6-[[((4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl)oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-87-9 CAPLUS  
CN 2-Phenanthrenol, 7-((3-amino-4-methyl-2-pyridinyl)oxy)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-91-5 CAPLUS  
CN 3-Pyridinecarbonitrile, 2-[[((4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-93-7 CAPLUS  
CN 2-Pyridinecarbonitrile, 6-[(4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl)oxy]- (9CI) (CA INDEX NAME)




RN 305828-94-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-[(6-(trifluoromethyl)-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)




RN 305828-95-9 CAPLUS  
CN 2-Pyridinecarbonitrile, 6-{{(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl}oxy}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-96-0 CAPLUS  
CN 3-Pyridinecarbonitrile, 4,6-dimethyl-2-{{(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl}oxy}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-97-1 CAPLUS  
CN 3-Pyridinecarbonitrile, 6-{{(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl}oxy}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 305829-01-0 CAPLUS  
CN 2-Phenanthrenol, 7-[(2,6-dimethoxy-4-pyrimidinyl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-02-1 CAPLUS  
CN 2-Phenanthrenol, 7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305828-98-2 CAPLUS  
CN 3-Pyridinecarbonitrile, 6-{{(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl}oxy}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305828-99-3 CAPLUS  
CN 3-Pyridinecarbonitrile, 4,6-dimethyl-2-{{(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl}oxy}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-00-9 CAPLUS  
CN 2-Phenanthrenol, 7-[(2,6-dichloro-4-pyrimidinyl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 305829-03-2 CAPLUS  
CN 2-Phenanthrenol, 7-[(6-chloro-2-pyridinyl)oxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-04-3 CAPLUS  
CN 2-Pyridinecarbonitrile, 3-{{(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl}oxy}methyl}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-05-4 CAPLUS  
CN 2-Pyridinecarbonitrile, 3-{{(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl}oxy}methyl}- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-06-5 CAPLUS


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methoxy-6-methyl-4-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-07-6 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(2-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-08-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(2-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(4-pyrimidinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-13-4 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-methyl-2-[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-14-5 CAPLUS  
 CN 2-Phenanthrenol, 7-[(4,6-dimethyl-2-pyrimidinyl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305829-09-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methoxy-3-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-10-1 CAPLUS  
 CN 2(1H)-Pyridinone, 3-[[{(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-(phenylmethyl)-7-propyl-2-phenanthrenyl}oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-11-2 CAPLUS

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-15-6 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(3-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-16-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-7-(4-quinolinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-17-8 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(3-methyl-2-quinoxalinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-18-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methyl-3-isoxazolyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
INDEX NAME)

Absolute stereochemistry.




RN 305829-23-6 CAPLUS  
CN 3-Pyridinecarbonitrile, 6-[(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl]oxy]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-24-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methoxypropyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-32-7 CAPLUS  
CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-34-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-5-thiazolyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-35-0 CAPLUS  
CN 2-Phenanthrenol, 7-[(5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305829-25-8 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(6-methoxy-2-pyridinyl)methoxy]-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-31-6 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(methoxymethyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-36-1 CAPLUS  
CN 2-Phenanthrenol, 7-[(5-(3,5-dimethyl-4-isoxazolyl)-1,2,4-oxadiazol-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-propyl-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-37-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(3-methoxy-1-propynyl)-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-47-4 CAPLUS  
CN 2-Phenanthrenol, 2-(3,3-dimethylbutyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-50-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(2-phenylethyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-51-0 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-52-1 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-[(2,2,2-trifluoroethoxy)methyl]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-[(2-pyridinylmethoxy)methyl]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-56-5 CAPLUS  
 CN Propanenitrile, 3-[(2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-2-hydroxy-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-phenanthrenyl]methoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-57-6 CAPLUS  
 CN 2-Phenanthrenol, 2-[(cyclopentyloxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305829-53-2 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(1-methylethoxy)methyl]-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-54-3 CAPLUS  
 CN 2-Phenanthrenol, 2-(azidomethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-55-4 CAPLUS


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 305829-58-7 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(3-methyl-3-oxetanyl)methoxy]-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-59-8 CAPLUS  
 CN 2-Phenanthrenol, 2-[(1,1-dimethylethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-60-1 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(phenoxy)methyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 305829-65-6 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-[2-(2-pyridinylmethyl)ethyl]-7-(3-pyridinylmethoxy)-, (2S,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-66-7 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(methylthio)methyl]-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-67-8 CAPLUS


CN 2-Phenanthrenol, 2-[(cyclobutyloxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN 2-Phenanthrenol, 2-[(2,2-dimethylpropoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-71-4 CAPLUS

CN 2-Phenanthrenol, 2-[(2-ethylbutoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 305829-72-5 CAPLUS

CN 2-Phenanthrenol, 2-[(2-butynylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 305829-68-9 CAPLUS

CN 2-Phenanthrenol, 2-[(2-fluoroethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-69-0 CAPLUS

CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(2-methylthio)ethyl]-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-70-3 CAPLUS

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 305829-73-6 CAPLUS

CN 2-Phenanthrenol, 2-[(cyclohexylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-74-7 CAPLUS

CN 2-Phenanthrenol, 2-[(cyclopentylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-75-8 CAPLUS

CN 2-Phenanthrenol, 2-[(cyclobutylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 305829-76-9 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-[(3-phenyl-1-propynyl)oxy]methoxy-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-77-0 CAPLUS  
 CN 2-Phenanthrenol, 2-[(3-fluoro-3-methyl-1-butynyl)oxy]methoxy-, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-78-1 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-(1H-imidazol-1-ylmethyl)-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methyl-3-isoxazolyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-83-8 CAPLUS  
 CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[2-(4-morpholinyl)ethoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305829-84-9 CAPLUS  
 CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(pyrazinylloxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305829-85-0 CAPLUS  
 CN 2-Phenanthrenol, 7-[(2-amino-6-methyl-4-pyrimidinyl)oxy]-2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305829-79-2 CAPLUS  
 CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(3-pyridinylmethoxy)-2-(1H-1,2,4-triazol-1-ylmethyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-81-6 CAPLUS  
 CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-82-7 CAPLUS

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305829-86-1 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[(4bS,7R,8aR)-7-(ethoxymethyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl]oxy)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-88-3 CAPLUS  
 CN 2-Phenanthrenol, 2-(cyclopropylethynyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-89-4 CAPLUS  
 CN 2-Phenanthrenol, 2-(cyclopropylethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 305829-90-7 CAPLUS  
CN 2-Phenanthrenol, 2-(2-cyclopropylethyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-91-8 CAPLUS  
CN 2-Phenanthrenol, 2-(2-cyclopropylethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305830-00-6 CAPLUS  
CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-4-thiazolyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305830-01-7 CAPLUS  
CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(5-methyl-3-isoxazolyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305830-02-8 CAPLUS  
CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-4-thiazolyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


RN 305829-92-9 CAPLUS  
CN 2-Pyridinecarbonitrile, 3-[[{(4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-2-phenanthrenyl}oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-94-1 CAPLUS  
CN 2-Phenanthrenol, 2-[(cyclobutoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(1-oxido-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305829-97-4 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-[(2-(1H-pyrazol-1-yl)ethoxy)methyl]-7-(3-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305830-03-9 CAPLUS  
CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-7-(2-pyridinylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305830-04-0 CAPLUS  
CN 2-Phenanthrenol, 2-[(cyclopropylmethoxy)methyl]-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305830-05-1 CAPLUS  
CN 2-Phenanthrenol, 2-(ethoxymethyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylmethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Absolute stereochemistry.




RN 305830-21-1 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-[(1-methylethoxy)methyl]-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylimethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305830-22-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylimethyl)-2-[(2,2,2-trifluoroethoxy)methyl]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 305822-69-9P 305823-16-9P 305823-19-2P  
305823-20-5P 305823-24-9P 305823-25-0P  
305823-27-2P 305823-28-3P 305823-29-4P  
305823-30-7P 305823-32-9P 305823-33-0P  
RL: RCT (Reactant); SPA (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of nonracemic octahydrophenanthrene and other tricyclic derivs.  
as selective modulators of glucocorticoid receptors)

RN 305822-69-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(5-(4-morpholinyl)pentyloxy)-4a-(phenylimethyl)-2-propyl], (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305823-16-9 CAPLUS  
CN 4-Morpholinecarboxylic acid, (4bS,7R,8aR)-7-(chloroethyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylimethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
RN 305830-37-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-2-(1-pentylyn)-4a-(phenylimethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305830-47-1 CAPLUS  
CN 2-Phenanthrenol, 2-(1-butynyl)-1,2,3,4,4a,9,10,10a-octahydro-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylimethyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305830-54-0 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-2-methyl-7-[(2-methyl-3-pyridinyl)methoxy]-4a-(phenylimethyl)-, (2R,4aS,10aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 305823-19-2 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylimethyl)-2-(1-propynyl)-7-[(3-pyrazinyl-1,2,4-oxadiazol-5-yl)methoxy]-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305823-20-5 CAPLUS  
CN 2-Phenanthrenol, 7-[(5-amino-1H-1,2,4-triazol-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylimethyl)-2-(1-propynyl)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305823-24-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylimethyl)-2-(1-propynyl)-7-(1H-tetrazol-5-ylmethoxy)-, (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305823-25-0 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-(2-(4-methyl-1-piperazinyl)ethoxy)-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305823-27-2 CAPLUS  
CN 2-Phenanthrenol, 7-[(5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl)methoxy]-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305823-28-3 CAPLUS  
CN 1,2,4-Oxadiazol-5(2H)-one, 3-[(14bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.



RN 305823-33-0 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-((2-(4-morpholinyl)-4-pyrimidinyl)oxy)-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RN 305823-29-4 CAPLUS  
CN 1,2,4-Oxadiazole-5(2H)-thione, 3-[(14bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305823-30-7 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-7-((5-(2-(4-morpholinyl)ethyl)-1,2,4-oxadiazol-3-yl)methoxy)-4a-(phenylmethyl)-2-(1-propynyl)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 305823-32-9 CAPLUS  
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-7-(pyrazinyl)oxy)-, (2R,4aS,10aR)-(9CI) (CA INDEX NAME)